These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

103 related articles for article (PubMed ID: 15928819)

  • 1. Selective H3 receptor (H3R) blockade: broad efficacy in cognition and schizophrenia.
    Fox GB; Esbenshade TA; Pan JB; Browman KE; Zhang M; Ballard ME; Radek RJ; Miner H; Bitner RS; Krueger KM; Yao BB; Faghih R; Rueter LE; Komater VA; Drescher KU; Buckley MJ; Sullivan JP; Cowart MD; Decker MW; Hancock AA
    Inflamm Res; 2005 Apr; 54 Suppl 1():S23-4. PubMed ID: 15928819
    [No Abstract]   [Full Text] [Related]  

  • 2. Pharmacological properties of ABT-239 [4-(2-{2-[(2R)-2-Methylpyrrolidinyl]ethyl}-benzofuran-5-yl)benzonitrile]: II. Neurophysiological characterization and broad preclinical efficacy in cognition and schizophrenia of a potent and selective histamine H3 receptor antagonist.
    Fox GB; Esbenshade TA; Pan JB; Radek RJ; Krueger KM; Yao BB; Browman KE; Buckley MJ; Ballard ME; Komater VA; Miner H; Zhang M; Faghih R; Rueter LE; Bitner RS; Drescher KU; Wetter J; Marsh K; Lemaire M; Porsolt RD; Bennani YL; Sullivan JP; Cowart MD; Decker MW; Hancock AA
    J Pharmacol Exp Ther; 2005 Apr; 313(1):176-90. PubMed ID: 15608077
    [TBL] [Abstract][Full Text] [Related]  

  • 3. 4-(2-[2-(2(R)-methylpyrrolidin-1-yl)ethyl]benzofuran-5-yl)benzonitrile and related 2-aminoethylbenzofuran H3 receptor antagonists potently enhance cognition and attention.
    Cowart M; Faghih R; Curtis MP; Gfesser GA; Bennani YL; Black LA; Pan L; Marsh KC; Sullivan JP; Esbenshade TA; Fox GB; Hancock AA
    J Med Chem; 2005 Jan; 48(1):38-55. PubMed ID: 15634000
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Antiobesity evaluation of histamine H3 receptor (H3R) antagonist analogs of A-331440 with improved safety and efficacy.
    Hancock AA; Diehl MS; Fey TA; Bush EN; Faghih R; Miller TR; Krueger KM; Pratt JK; Cowart MD; Dickinson RW; Shapiro R; Knourek-Segel VE; Droz BA; McDowell CA; Krishna G; Brune ME; Esbenshade TA; Jacobson PB
    Inflamm Res; 2005 Apr; 54 Suppl 1():S27-9. PubMed ID: 15928821
    [No Abstract]   [Full Text] [Related]  

  • 5. Two novel and selective nonimidazole H3 receptor antagonists A-304121 and A-317920: II. In vivo behavioral and neurophysiological characterization.
    Fox GB; Pan JB; Radek RJ; Lewis AM; Bitner RS; Esbenshade TA; Faghih R; Bennani YL; Williams M; Yao BB; Decker MW; Hancock AA
    J Pharmacol Exp Ther; 2003 Jun; 305(3):897-908. PubMed ID: 12606600
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Achievement of behavioral efficacy and improved potency in new heterocyclic analogs of benzofuran H3 antagonists.
    Cowart M; Faghih R; Gfesser G; Curtis M; Sun M; Zhao C; Bennani Y; Wetter J; Marsh K; Miller TR; Krueger K; Pan JB; Drescher K; Fox GB; Esbenshade TA; Hancock AA
    Inflamm Res; 2005 Apr; 54 Suppl 1():S25-6. PubMed ID: 15928820
    [No Abstract]   [Full Text] [Related]  

  • 7. Do Histamine receptor 3 antagonists have a place in the therapy for schizophrenia?
    Ellenbroek BA; Ghiabi B
    Curr Pharm Des; 2015; 21(26):3760-70. PubMed ID: 26044979
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Synthesis and SAR of 5-amino- and 5-(aminomethyl)benzofuran histamine H3 receptor antagonists with improved potency.
    Sun M; Zhao C; Gfesser GA; Thiffault C; Miller TR; Marsh K; Wetter J; Curtis M; Faghih R; Esbenshade TA; Hancock AA; Cowart M
    J Med Chem; 2005 Oct; 48(20):6482-90. PubMed ID: 16190774
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Pharmacological properties of ABT-239 [4-(2-{2-[(2R)-2-Methylpyrrolidinyl]ethyl}-benzofuran-5-yl)benzonitrile]: I. Potent and selective histamine H3 receptor antagonist with drug-like properties.
    Esbenshade TA; Fox GB; Krueger KM; Miller TR; Kang CH; Denny LI; Witte DG; Yao BB; Pan L; Wetter J; Marsh K; Bennani YL; Cowart MD; Sullivan JP; Hancock AA
    J Pharmacol Exp Ther; 2005 Apr; 313(1):165-75. PubMed ID: 15608078
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Lack of cataleptogenic potentiation with non-imidazole H3 receptor antagonists reveals potential drug-drug interactions between imidazole-based H3 receptor antagonists and antipsychotic drugs.
    Zhang M; Ballard ME; Pan L; Roberts S; Faghih R; Cowart M; Esbenshade TA; Fox GB; Decker MW; Hancock AA; Rueter LE
    Brain Res; 2005 May; 1045(1-2):142-9. PubMed ID: 15910772
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Donepezil, an acetylcholine esterase inhibitor, and ABT-239, a histamine H3 receptor antagonist/inverse agonist, require the integrity of brain histamine system to exert biochemical and procognitive effects in the mouse.
    Provensi G; Costa A; Passani MB; Blandina P
    Neuropharmacology; 2016 Oct; 109():139-147. PubMed ID: 27291828
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Histamine-selective H3 receptor ligands and cognitive functions: an overview.
    Vohora D
    IDrugs; 2004 Jul; 7(7):667-73. PubMed ID: 15243869
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Histamine H3 receptor antagonists: preclinical promise for treating obesity and cognitive disorders.
    Esbenshade TA; Fox GB; Cowart MD
    Mol Interv; 2006 Apr; 6(2):77-88, 59. PubMed ID: 16565470
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Discovery of spirofused piperazine and diazepane amides as selective histamine-3 antagonists with in vivo efficacy in a mouse model of cognition.
    Brown DG; Bernstein PR; Griffin A; Wesolowski S; Labrecque D; Tremblay MC; Sylvester M; Mauger R; Edwards PD; Throner SR; Folmer JJ; Cacciola J; Scott C; Lazor LA; Pourashraf M; Santhakumar V; Potts WM; Sydserff S; Giguère P; Lévesque C; Dasser M; Groblewski T
    J Med Chem; 2014 Feb; 57(3):733-58. PubMed ID: 24410637
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effects of the histamine H₃ receptor antagonist ABT-239 on cognition and nicotine-induced memory enhancement in mice.
    Kruk M; Miszkiel J; McCreary AC; Przegaliński E; Filip M; Biała G
    Pharmacol Rep; 2012; 64(6):1316-25. PubMed ID: 23406742
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Two novel and selective nonimidazole histamine H3 receptor antagonists A-304121 and A-317920: I. In vitro pharmacological effects.
    Esbenshade TA; Krueger KM; Miller TR; Kang CH; Denny LI; Witte DG; Yao BB; Fox GB; Faghih R; Bennani YL; Williams M; Hancock AA
    J Pharmacol Exp Ther; 2003 Jun; 305(3):887-96. PubMed ID: 12606603
    [TBL] [Abstract][Full Text] [Related]  

  • 17. In-vivo histamine H3 receptor antagonism activates cellular signaling suggestive of symptomatic and disease modifying efficacy in Alzheimer's disease.
    Bitner RS; Markosyan S; Nikkel AL; Brioni JD
    Neuropharmacology; 2011; 60(2-3):460-6. PubMed ID: 21044639
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Medicinal chemistry and biological properties of non-imidazole histamine H3 antagonists.
    Cowart M; Altenbach R; Black L; Faghih R; Zhao C; Hancock AA
    Mini Rev Med Chem; 2004 Nov; 4(9):979-92. PubMed ID: 15544558
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Anxiety and cognition in histamine H3 receptor-/- mice.
    Rizk A; Curley J; Robertson J; Raber J
    Eur J Neurosci; 2004 Apr; 19(7):1992-6. PubMed ID: 15078574
    [TBL] [Abstract][Full Text] [Related]  

  • 20. In vitro optimization of structure activity relationships of analogues of A-331440 combining radioligand receptor binding assays and micronucleus assays of potential antiobesity histamine H3 receptor antagonists.
    Hancock AA; Diehl MS; Faghih R; Bush EN; Krueger KM; Krishna G; Miller TR; Wilcox DM; Nguyen P; Pratt JK; Cowart MD; Esbenshade TA; Jacobson PB
    Basic Clin Pharmacol Toxicol; 2004 Sep; 95(3):144-52. PubMed ID: 15447739
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.